CSF IGG ANALYSIS IN MULTIPLE SCLEROSIS

多发性硬化症(MS)的脱髓鞘是由炎症引起的 这个过程似乎是由免疫调节的。发起的抗原(S) 或者是否受伤都是未知数。我们建议将可溶性免疫描述为 从脑脊液中分离出的复合体(ICx) 患有多发性硬化症和其他神经系统疾病的患者。可溶性ICX将是 ~(125)I标记铁蛋白结合物在液体相中的分离 抗Ig G单抗(抗Ig G-F)。高密度的 铁蛋白提高可溶性ICX的有效S转化率 特征外观同时提供了一种超微结构标记 对ICX来说。电子显微镜检查将使用负染色法 改善大分子细节的技术，并希望线索 关于假定抗原的性质的问题将会公布，特别是 如果相关抗原是病毒来源的。可溶性免疫中的抗原 复合体将使用聚丙烯酰胺凝胶电泳法进行分析 再加上免疫染色分离的蛋白质的“斑点” 十二烷基硫酸钠-PAGE。类似的化验将被用来显示抗体的存在。 在脑脊液中定向到个别蛋白条带。最后， 将单抗提高到分离可溶性ICx并进行筛选 对于它们与ICx的反应性，以及最终被 电泳法，再用“Western Blot”技术。通过这些 研究，我们希望确定重要的物理和生化特性 可能对多发性硬化症和其他疾病有致病意义的抗原 神经系统疾病。最终，这应该会导致新的和具体的 免疫治疗的策略。

Demyelination in Multiple Sclerosis (MS) results from an inflammatory process that appears to be immune mediated. The antigen(s) which initiate or sustain injury are unknown. We propose to characterize soluble immune complexes (ICx) that have been isolated from the cerebrospinal fluid (CSF) of patients with MS and other neurological disordes. Soluble ICx will be isolated in the fluid phase with ferritin conjugates of 125I-labeled monoclonal anti-IgG antibodies (anti-IgG-F). The high density of the ferrintin increases the effective s-rate of soluble ICx while its characteristic appearance simultaneously provides an ultrastructural marker for the ICx. Electron microscopy will be performed using negative staining techniques to improve macromolecular detail and with the hope that clues regarding the nature of putative antigens will be forthcoming, especially if relevant antigens are of viral origin. Antigen within soluble immune complexes will be analyzed utilizing polyacrylamide gel electrophoresis coupled with immunologic staining of "blots" of protein separated by SDS-PAGE. Similar assays will be used to show the presence of antibodies within CSF that are directed to the individual protein bands. Finally, monoclonal antibodies will be raised to separated soluble ICx and screened for their reactivity with ICx and eventually the various bands separated by electrophoresis, again with the "Western Blot" technique. By these studies, we hope to determine important physical and biochemical properties of antigens that may have pathogenic significance in MS and other neurological diseases. Ultimately, this should lead to new and specific strategies for immunotherapy.